# Broermann Medical Innovation Award 2026: Three Pioneers of Modern Obesity and Diabetes Therapies Honored

- Link: https://www.thailand-business-news.com/pr-news/broermann-medical-innovation-award-2026-three-pioneers-of-modern-obesity-and-diabetes-therapies-honored
- Published: 2026-11-17T22:47:00+07:00
- Author: Media OutReach

*  Prof. Svetlana Mojsov, Prof. Dr. Richard DiMarchi, and Prof. Dr. Dr. h.c. Matthias
   H. Tschöp honored for groundbreaking research on metabolic diseases and obesity
   therapies.
 *  Minister-President Boris Rhein presents the medical award, endowed with a total
   of one million euros, at the Hessian State Chancellery.
 *  Titia große Broermann: ” this year’s laureates powerfully demonstrate how scientific
   curiosity sparks medical progress that can transform millions of lives”

 WIESBADEN, GERMANY – Newsaktuell – 17 November 2026 – Prof. Svetlana Mojsov (The
Rockefeller University), Prof. Dr. Richard DiMarchi (Indiana University), and Prof.
Dr. Dr. h.c. Matthias H. Tschöp (Ludwig-Maximilians-Universität München) have been
awarded the Broermann Medical Innovation Award 2026. Hessian Minister-President 
Boris Rhein presented the award during a ceremony at the Hessian State Chancellery.

 Endowed with a total of one million euros, the Broermann Medical Innovation Award
ranks among the world´s highest-endowed medical honors. This year, it honors three
scientists whose fundamental work contributed decisively to enabling modern GLP-
1-based therapies against obesity and diabetes. The award was endowed by Dr. Bernard
große Broermann, founder of the Asklepios Kliniken Group.

 In the presence of representatives from science, politics, and society, Minister-
President Boris Rhein praised the international significance of the honored research
achievements:

 Boris Rhein, Minister-President of Hesse: “Through their research, Prof. Dr. Richard
D. DiMarchi, Prof. Dr. Svetlana Mojsov, and Prof. Dr. med. Dr. h.c. Matthias Tschöp
have opened a new chapter in metabolic therapy. Their work laid the scientific foundation
for what is colloquially known as the “weight-loss injection.” From fundamental 
insights into human metabolism, a new generation of therapies has emerged, paving
the way for effective treatments for diabetes and obesity, while also helping to
manage or reduce associated secondary conditions.”

 Prof. Dr. Werner Seeger, Chairman of the Jury for the Broermann Award, emphasized:“
The work of this year’s laureates powerfully proves how scientific pioneering transforms
into medical reality. Their discoveries surrounding GLP-1 and polyagonists have 
fundamentally redefined obesity and diabetes care, offering real hope to millions
worldwide.”

 Prof. Svetlana Mojsov stated: “I am humbled and honored to receive the Broermann
Award for my work on GLP-1 that began over 40 years ago with a hypothesis and has
gone to benefit the health and lives of millions of people worldwide.”

 Prof. Dr. Richard DiMarchi noted: ” In the last decade, based upon a half century
of research we have progressed with incretin-based medicines to transform the management
of excess body weight analogous to historical treatment of excess glucose, cholesterol,
and blood pressure. It is providing a transformative advance in public health and
patient well-being.”

 Prof. Dr. Dr. h.c. Matthias H. Tschöp added: “It is a great honor to receive this
recognition together with Svetlana Mojsov and Richard DiMarchi. We are delighted
that our decades of work on the scientific foundation and invention of therapeutic
principles that ignited the modern obesity-drug revolution is receiving international
recognition. It is especially rewarding to see how these discoveries are transforming
the therapeutic landscape of diabetes, cardiovascular disease, fatty liver disease,
and many other obesity-related conditions worldwide.”

 Titia Olivia große Broermann, Shareholder of the Asklepios Kliniken Group, added:“
The Broermann Medical Innovation Award stands for the conviction that medical progress
begins where scientific courage meets the determination to sustainably improve patients’
lives. This year’s awardees impressively demonstrate how scientific curiosity and
decades of research can give rise to therapies that transform the lives of millions
of people. With this award, we aim to make their outstanding achievements visible
while encouraging researchers worldwide to forge new paths. On behalf of my family
and the Asklepios Kliniken Group, I congratulate Prof. Mojsov, Prof. DiMarchi, and
Prof. Tschöp from the bottom of my heart.”

 **Foundations for a New Generation of Therapies**

 Prof. Svetlana Mojsov, Prof. Dr. Richard DiMarchi, and Prof. Dr. Dr. h.c. Matthias
H. Tschöp were honord for their fundamental contributions to metabolic science. 
Their work on elucidating bioactive GLP-1, signal transmission between the gut and
brain, and the development of multi-hormone co-agonists (polyagonists) laid the 
foundation for modern drugs for weight regulation and blood sugar control.

 **About the Award Winners**

 Prof. Svetlana Mojsov (born in Skopje, North Macedonia) earned her PhD in biochemistry
at The Rockefeller University under Nobel laureate Bruce Merrifield, focusing on
solid-phase peptide synthesis. During her research at Massachusetts General Hospital
and Harvard Medical School in the 1980s, she identified and chemically synthesized
the active 31-amino-acid form of Glucagon-Like Peptide-1 (GLP-1) and demonstrated
its physiological role in stimulating insulin secretion. Her groundbreaking discoveries
proved vital for the later development of GLP-1 receptor agonists. She currently
serves as a Research Professor at The Rockefeller University in New York.

 Prof. Dr. Richard DiMarchi (born in New York, USA) earned his PhD in biochemistry
at Indiana University. Following academic research at The Rockefeller University,
he led major research and development divisions at Eli Lilly and Company for over
two decades, where he played a pioneering role in shaping the development of human
insulin and analogues (Humalog®) and rHGH (Humatrope®) As a world-renowned peptide
chemist and innovator, he holds over 100 patents and has co-founded eight successful
biotech companies. He is currently Distinguished Professor of Chemistry and Gill
Chair in Biomolecular Sciences at Indiana University.

 Prof. Dr. Dr. h.c. Matthias H. Tschöp (born in Munich, Germany) completed his medical
studies at Ludwig-Maximilians-Universität (LMU) München. Following clinical work
in endocrinology and research at Eli Lilly, he established research laboratories
at the University of Cincinnati and Helmholtz Munich. Tschöp discovered the key 
role of ghrelin as the hunger hormon and, in close collaboration with Richard DiMarchi,
developed the concept of multi-hormone co-agonists (dual and triple gut hormone 
receptor agonists such as GLP-1/GIP and GLP-1/GIP/glucagon molecules). He currently
serves as President of LMU Munich.

 **About the Broermann Medical Innovation Award**

 The **Broermann Medical Innovation Award** was established in 2024 by Dr. Bernard
große Broermann, namesake and founder of Asklepios Kliniken. Throughout his lifetime,
Dr. große Broermann was distinguished by his vision of creating an innovative healthcare
company that delivers genuine benefits to people. Under his leadership, Asklepios
set standards in medical innovation, targeted investments in state-of-the-art medical
technology and digital solutions, and thereby advanced patient care—values that 
also

 form the foundation of the Broermann Medical Innovation Award. Through this award,
his vision lives on and underscores a commitment that endures beyond his lifetime
through his foundation.

 **2027 Nomination Phase**

 The nomination phase for the Broermann Medical Innovation Award 2027 has begun.
Scientists from around the world can be nominated until March 1, 2027. Further information
on the award, nomination criteria, and the selection process is available on the
[Award-Website](https://www.broermann-award.org/nomination/)

 **High-resolution photos of the award ceremony will be available for download shortly
after the event at the following website: **[https://www.broermann-award.org/press/](https://www.broermann-award.org/press/)

 **Broermann Medical Innovation Award** 
 [www.broermann-award.com](http://www.broermann-award.com)
[www.facebook.com/people/Broermann-Medical-Innovation-Award/61567211302915/](http://www.facebook.com/people/Broermann-Medical-Innovation-Award/61567211302915/)
[www.linkedin.com/company/broermann-medical-innovation-award/](http://www.linkedin.com/company/broermann-medical-innovation-award/)
[www.instagram.com/broermannaward](http://www.instagram.com/broermannaward)

 **Asklepios Kliniken** 
 Visit Asklepios online and on social media:  [www.asklepios.com](http://www.asklepios.com)
[www.asklepios.com/gesundheitsmagazin](http://www.asklepios.com/gesundheitsmagazin)
[http://www.youtube.com/asklepioskliniken](http://www.youtube.com/asklepioskliniken)
[de.linkedin.com/company/asklepios](https://de.linkedin.com/company/asklepios)  
[www.instagram.com/asklepioskliniken/](http://www.instagram.com/asklepioskliniken/)
[www.facebook.com/asklepioskliniken](http://www.facebook.com/asklepioskliniken)  
[www.tiktok.com/@asklepioskliniken](https://www.tiktok.com/@asklepioskliniken)

The issuer is solely responsible for the content of this announcement.

![](//track.media-outreach.com/index.php/WebView/502063/36955)

**Source** : [Broermann Medical Innovation Award 2026: Three Pioneers of Modern Obesity and Diabetes Therapies Honored](https://www.media-outreach.com/news/germany/2026/11/17/502063/?rand=186006)

---

  |  This article was produced by Media OutReach, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not reflect the opinions of Thailand Business News. |

---

![Media OutReach Newswire](https://r2.thailand-business-news.com/wp-content/uploads/
2026/10/media-outreach-newswire-2025.svg)
